ArticleFrontiers in nutrition2026
Non-HDL-to-HDL cholesterol ratio predicts incident T2DM and CHD in non-alcoholic fatty liver disease: evidence from a large clinical cohort and NHANES.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disorder linked to increased risk of type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). The Non-HDL-to-HDL Cholesterol Ratio (NHHR) is an emerging lipid marker, but its predictive value for T2DM and CHD in NAFLD patients is unclear. This study evaluated the association between NHHR and the incidence of T2DM and CHD in a large NAFLD cohort. Methods: We conducted a retrospective cohort study involving 13,741 NAFLD patients from the Affiliated Hospital of Guangdong Medical University (2018-2025) and validated our findings in NHANES cohort (1999-2018) comprising 5,789 individuals. Participants were stratified into quartiles, and multivariate logistic regression with restricted cubic splines assessed associations with incident T2DM and CHD, adjusting for confounders. Subgroup, interaction, and mediation analyses elucidated potential effect modifiers and mediators. Results: Higher NHHR was independently associated with an increased risk of T2DM in both cohorts (per unit increase: OR 1.08, 95% CI 1.06-1.11). A nonlinear dose-response relationship was observed, with a marked rise in T2DM risk at higher NHHR levels, and participants in the highest NHHR quartile had 67% higher odds of T2DM compared with the lowest quartile. Mediation analysis indicated that fasting glucose accounted for over half of the NHHR-T2DM association. In contrast, the association between NHHR and CHD was weaker and less consistent across cohorts, suggesting heterogeneity in its cardiovascular predictive value among patients with NAFLD. Findings for T2DM were robust across major subgroups and externally validated in NHANES. Conclusion: NHHR is a simple, readily available lipid index that independently predicts incident T2DM in patients with NAFLD. Its nonlinear risk pattern and partial mediation through glucose metabolism underscore its clinical utility for early risk stratification and personalized prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.